SCHEMBL4467032

SCHEMBL4467032

CCc1nc2ccccc2c(=O)n1-c1ccc(O)cc1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.76
LMNA P02545 1/20 0.76
ALDH1A1 P00352 4/20 0.73
ESR1 P03372 1/20 0.62
ESR2 Q92731 1/20 0.62
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
BLM P54132 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2D6 P10635 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
KCNH2 Q12809 1/20 0.58
HRH3 Q9Y5N1 1/20 0.58
PDE10A Q9Y233 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8649618 0.92 MAPK1 (0.67) MAPK1LMNAALDH1A1ESR1ESR2
SCHEMBL8242227 0.91 NPC1 (0.70) MAPK1LMNAALDH1A1MEN1KMT2A
SCHEMBL1484129 0.87 MEN1 (0.66) MAPK1LMNAALDH1A1MEN1KMT2A
SCHEMBL4957618 0.87 MAPK1 (0.60) MAPK1LMNAALDH1A1MEN1KMT2A
SCHEMBL4960948 0.87 MAPK1 (0.62) MAPK1LMNAALDH1A1MEN1KMT2A
SCHEMBL4957089 0.87 LMNA (1.00) MAPK1LMNAALDH1A1ESR1ESR2
SCHEMBL2118476 0.84 MAPK1 (0.76) MAPK1LMNAALDH1A1ESR1ESR2
SCHEMBL6439732 0.81 ESR2 (0.61) MAPK1LMNAALDH1A1ESR1ESR2
SCHEMBL15957753 0.81 ESR1 (0.63) MAPK1LMNAALDH1A1ESR1ESR2
SCHEMBL4955792 0.80 MEN1 (0.69) MAPK1LMNAALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1717230-B1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE MSD KK (JP) 2014-08-06 EP disclosed
US-8268842-B2 Fused ring 4-oxopyrimidine derivative MSD K.K. (JP) 2012-09-18 US disclosed
CN-1918128-B fused ring 4-oxo-pyrimidine derivatives BANYU PHARMA CO LTD 2011-01-26 CN disclosed
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-08-20 US disclosed
US-7521455-B2 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO. LTD. (JP) 2009-04-21 US disclosed
CN-1918128-A Fused ring 4-oxo-pyrimidine derivatives BANYU PHARMA CO LTD (JP) 2007-02-21 CN disclosed
EP-1743891-A1 Heterocyclic compounds and methods for modulating CXCR3 function ChemoCentryx Inc (US) 2007-01-17 EP disclosed
EP-1717230-A1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 MAPK1 2026/4885LMNA 4856/4885ALDH1A1 1717/4885
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 MAPK1 2026/4885LMNA 4856/4885ALDH1A1 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.